Skip to main content

Table 2 Dose Escalations for Each Sequential Cohort

From: Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study

  Study Days (Dose Numbers)
1–2 (1–6) 3–4 (7–12) 5–6 (13–18) 7–8 (19–24) 9–10 (25–30) 11–12 (31–36) 13–14 (37–42) 15 + (43 +)
Sildenafil Dose (mg/kg)
Cohort 1
 IV 0.25 0.5 0.5 0.5 0.5 0.5 0.5 0.5
 Enteral 0.5 1 1 1 1 1 1 1
Cohort 2
 IV 0.25 0.5 0.75 1 1 1 1 1
 Enteral 0.5 1 1.5 2 2 2 2 2
Cohort 3
 IV 0.25 0.5 0.75 1 1.5 1.75 2 2
 Enteral 0.5 1 1.5 2 3 3.5 4 4
  1. Abbreviation: IV intravenous